Skip to content

Depressive symptomatology in young adults with a history of MDMA use: a longitudinal analysis

Rüssel S. Falck, Jichuan Wang, Robert G. Carlson

Journal of Psychopharmacology August 22, 2007 DOI: 10.1177/0269881107078293 (opens in new tab)

Study at a glance

AI-extracted from the abstract
Characteristics Longitudinal study Peer reviewed
Sample size 402
Population Young adult MDMA/ecstasy users from the community
Duration 2-year follow-up with assessments every six months
Topics Anxiety MDMA
Keywords Depression economics Longitudinal study Beck depression inventory Young adult Clinical psychology Demography Developmental psychology
Citations 45
Key findings Depressive symptoms declined over two years among young adult MDMA users, suggesting that MDMA use does not result in long-term depressive symptomatology for most people.

Abstract

Research suggests that methylenedioxymethamphetamine (MDMA)/`ecstasy' can cause serotonin depletion as well as serotonergic neurodegradation that may result in depression. This longitudinal study used the Beck Depression Inventory (BDI-II) to assess depressive symptomatology every six months over a two-year period among a community sample of young adult MDMA/`ecstasy' users ( n = 402). Multilevel growth modeling was used to analyze changes in BDI scores. Between baseline and 24 months, the mean BDI score declined from 9.8 to 7.7. Scores varied significantly across individuals at baseline and declined at a rate of 0.36 points every six months. Persons with higher baseline scores were more likely to have their scores decrease over time. Several factors were significantly associated with score levels, independent of time: gender — men's scores were lower than women's; ethnicity — whites' scores were lower than those of non-whites; education — persons with at least some university education had scores that were lower than those without any college experience; benzodiazepines — current users' scores were higher than non-users'; opioids — current users' scores were higher than non-users'; and cumulative ecstasy use — people who had used MDMA more than 50 times had scores that were higher than persons who had used the drug less often. The results reported here show low levels of depressive symptoms among a sample that, after 24 months, consisted of both current and former MDMA users. The low and declining mean scores suggest that for most people MDMA/`ecstasy' use does not result in long-term depressive symptomatology.

Comparable studies

Other observational and cohort studies on MDMA for anxiety, most cited first.

Study Year Design Participants
Former chronic methylenedioxymethamphetamine (MDMA or ecstasy) users report mild depressive symptoms Former chronic ecstasy users 2001 Observational cohort n = 29
No Difference in Brain Activation During Cognitive Performance Between Ecstasy (3,4-Methylenedioxymethamphetamine) Users and Control Subjects: A [H215O]-Positron Emission Tomography Study Regular polytoxic Ecstasy users and Ecstasy-naive controls 2001 Observational cohort
Mood state and brain electric activity in Ecstasy users Ecstasy users and Ecstasy-naive controls 2000 Observational cohort n = 29
Symptoms of anxiety and depression in childhood and use of MDMA: prospective, population based study Children and adolescents from the Dutch province of Zuid-Holland 2006 Prospective longitudinal population-based study n = 1,580
Peri-traumatic consumption of classic psychedelics is associated with lower anxiety and post-traumatic responses 3 weeks after exposure. Adult survivors of a single large-scale terrorist attack at a festival 2025 Observational cohort n = 343

Explore topics

By condition and practice